Agilent Technologies Inc. (NYSE: A) and today announced that they have entered a co-marketing agreement. The announcement is happening at the being held February 29 through March 5, 2020, in Los Angeles, CA.
Based on a joint vision of end-to-end quality and standardization of tissue diagnostics, the partnership will address the currently unmet needs of pathology labs around the world. The companies’ shared goal is to provide specific technologies, produ--cts, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.Agilent and Visiopharm will co-market Visiopharm’s portfolio of artificial intelligence-driven pathology solutions.
“The transformation into next-generation precision pathology is important to realize the full potential of tissue pathology in this dawning era of personalized medicine,” said Michael Grunkin, CEO of Visiopharm. “This transformation requires a holistic approach to standardization along the entire diagnostic journey from biopsy to diagnosis. We are excited to be working with Agilent on precisely that. With their complementary product portfolio and longstanding legacy of innovation and quality in this field, we see a very strong match.”